Sept. 4 Company Quick Takes: Boehringer licenses Lupin MEK inhibitor; plus BMS-BioMotiv, KemPharm-GPC, Lilly, Nektar and Intellipharmaceutics
BI licenses Lupin's MEK inhibitor
Boehringer Ingelheim (Ingelheim, Germany) licensed development and commercialization rights to MEK inhibitor LNP3794 from Lupin Ltd. (NSE:LUPIN; BSE:500257), which the pharma plans to test in combination with its KRAS inhibitors for gastrointestinal and lung cancers with KRAS mutations. Mumbai-based Lupin will receive $20 million up front and is eligible for more than $700 million in clinical, regulatory and commercial milestones plus double-digit royalties.
BMS partners with BioMotiv to form newcos
Bristol-Myers Squibb Co. (NYSE:BMY) partnered with pharmaceutical accelerator BioMotiv LLC (Cleveland, Ohio) to fund and form companies across multiple disease areas. BMS will become an LP of BioMotiv and has an option to invest in additional projects and, upon identification of a preclinical candidate, an option to acquire the BioMotiv company under pre-agreed terms. Details were not disclosed...